English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4.76 |
| Open | 4.63 |
| 1-Year Change | -24.96% |
| Day's Range | 4.63 - 4.92 |
Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.
BRIEF: For the fiscal year ended 31 December 2021, Ocular Therapeutix Inc revenues increased from $17.4M to $43.5M. Net loss decreased 96% to $6.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of derivative liab. increase from $86.2M (expense) to $78.1M (income), Interest Expense decrease of 1% to $6.7M (expense).
